TY - JOUR
T1 - Drug delivery of natural products through nanocarriers for effective breast cancer therapy
T2 - A comprehensive review of literature
AU - Yap, Kah Min
AU - Sekar, Mahendran
AU - Fuloria, Shivkanya
AU - Wu, Yuan Seng
AU - Gan, Siew Hua
AU - Mat Rani, Nur Najihah Izzati
AU - Subramaniyan, Vetriselvan
AU - Kokare, Chandrakant
AU - Lum, Pei Teng
AU - Begum, M Yasmin
AU - Mani, Shankar
AU - Meenakshi, Dhanalekshmi Unnikrishnan
AU - Sathasivam, Kathiresan V
AU - Fuloria, Neeraj Kumar
N1 - Publisher Copyright:
© 2021 Yap et al.
PY - 2021
Y1 - 2021
N2 - Despite recent advances in the diagnosis and treatment of breast cancer (BC), it remains a global health issue affecting millions of women annually. Poor prognosis in BC patients is often linked to drug resistance as well as the lack of effective therapeutic options for metastatic and triple-negative BC. In response to these unmet needs, extensive research efforts have been devoted to exploring the anti-BC potentials of natural products owing to their multi-target mechanisms of action and good safety profiles. Various medicinal plant extracts/essential oils and natural bioactive compounds have demonstrated anti-cancer activities in preclinical BC models. Despite the promising preclinical results, however, the clinical translation of natural products has often been hindered by their poor stability, aqueous solubility and bioavailability. There have been attempts to overcome these limitations, particularly via the use of nano-based drug delivery systems (NDDSs). This review highlights the tumour targeting mechanisms of NDDSs, the advantages and disadvantages of the major classes of NDDSs and their current clinical status in BC treatment. Besides, it also discusses the proposed anti-BC mechanisms and nanoformulations of nine medicinal plants' extracts/essential oils and nine natural bioactive compounds; selected via the screening of various scientific databases, including PubMed, Scopus and Google Scholar, based on the following keywords: "Natural Product AND Nanoparticle AND Breast Cancer". Overall, these nanoformulations exhibit improved anti-cancer efficacy against preclinical BC models, with some demonstrating biocompatibility with normal cell lines and mouse models. Further clinical studies are, however, warranted to ascertain their efficacy and biocompatibility in humans.
AB - Despite recent advances in the diagnosis and treatment of breast cancer (BC), it remains a global health issue affecting millions of women annually. Poor prognosis in BC patients is often linked to drug resistance as well as the lack of effective therapeutic options for metastatic and triple-negative BC. In response to these unmet needs, extensive research efforts have been devoted to exploring the anti-BC potentials of natural products owing to their multi-target mechanisms of action and good safety profiles. Various medicinal plant extracts/essential oils and natural bioactive compounds have demonstrated anti-cancer activities in preclinical BC models. Despite the promising preclinical results, however, the clinical translation of natural products has often been hindered by their poor stability, aqueous solubility and bioavailability. There have been attempts to overcome these limitations, particularly via the use of nano-based drug delivery systems (NDDSs). This review highlights the tumour targeting mechanisms of NDDSs, the advantages and disadvantages of the major classes of NDDSs and their current clinical status in BC treatment. Besides, it also discusses the proposed anti-BC mechanisms and nanoformulations of nine medicinal plants' extracts/essential oils and nine natural bioactive compounds; selected via the screening of various scientific databases, including PubMed, Scopus and Google Scholar, based on the following keywords: "Natural Product AND Nanoparticle AND Breast Cancer". Overall, these nanoformulations exhibit improved anti-cancer efficacy against preclinical BC models, with some demonstrating biocompatibility with normal cell lines and mouse models. Further clinical studies are, however, warranted to ascertain their efficacy and biocompatibility in humans.
KW - breast cancer
KW - drug delivery
KW - molecular mechanisms
KW - nanoparticles
KW - natural products
KW - phytomedicine
UR - http://www.scopus.com/inward/record.url?scp=85122497471&partnerID=8YFLogxK
U2 - 10.2147/IJN.S328135
DO - 10.2147/IJN.S328135
M3 - Review Article
C2 - 34880614
AN - SCOPUS:85122497471
VL - 16
SP - 7891
EP - 7941
JO - International Journal of Nanomedicine
JF - International Journal of Nanomedicine
SN - 1178-2013
ER -